RxDoctor Payments Data

John Overbeck, MD

Cardiovascular Disease · Irving, TXNPI 1508865536

Payments from drug & device makers

$2,636in general payments, 2019–2025

Across 130 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$512
  • Novartis$467
  • AstraZeneca$296
  • Boehringer Ingelheim$225
  • Abbott$146
  • E.r. Squibb & Sons, L.L.C.$137
  • plus $851 from 16 others

What the payments were for

  • Food & beverage$2,636100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,636 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$328,781
Medicare patients
620
Services billed
2,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban346$351,289
XareltoRivaroxaban229$257,360
EntrestoSacubitril/Valsartan68$80,074
Repatha SureclickEvolocumab38$24,144
FarxigaDapagliflozin Propanediol19$20,315
JardianceEmpagliflozin22$19,207
VascepaIcosapent Ethyl18$15,247
Metoprolol Succinate497$7,301
Rosuvastatin Calcium344$4,681
Potassium Chloride206$3,945
Losartan Potassium338$3,388
Olmesartan Medoxomil177$2,870
Atorvastatin Calcium314$2,654
Carvedilol297$2,456
Flecainide Acetate52$2,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$512$351,289346 claims
Johnson & JohnsonXarelto$45$257,360229 claims
NovartisEntresto$467$80,07468 claims
AstraZenecaFarxiga$296$20,31519 claims
Boehringer IngelheimJardiance$225$19,20722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →